Bifrost Biosystems Pens Agreement with Illumina for Supply of Sequencing Chemistry for Optical Pooled Screening Platform

BERKELEY, Calif.--(BUSINESS WIRE)-- #AIDrugDiscovery--Bifrost Biosystems today announced that it has secured a commercial supply agreement with Illumina enabling integration of Illumina’s industry-standard sequencing-by-synthesis (SBS) chemistry into its optical pooled screening (OPS) platform slated to be commercially available in early 2027. OPS is a technology to link complex cellular phenotypes to the responsible genetic perturbation cost-effectively and at scale.The agreement provides reliable access to high-